Advertisement

Topics

Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy

08:13 EDT 6 Jun 2017 | BioPharma-Reporter

Hitachi Group subsidiary PCT Cell Therapy Services will provide clinical manufacturing services for Orchard’s autologous gene therapy for the treatment of adenosine deaminase deficiency.

Original Article: Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy

NEXT ARTICLE

More From BioPortfolio on "Orchard Therapeutics hits up Hitachi CDMO to make autologous gene therapy"

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...